Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Investors Liked What They Saw in Simcere's Q3 Report
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4...
- External links 2008-11-06
Additional Resources
- Simcere Acquires Statin Manufacturing License
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) has reached an agreement to acquire the manufacturing license of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. Rosuvastatin, a statin drug, is marketed as Crestor by AstraZeneca (NYSE: AZN) as a treatment for high cholesterol. Simcere will acquire equity in Tianda...
- External links 2009-11-10
- Simcere Issues Net Income Warning for 2008
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) announced that, according to preliminary figures, the company’s full-year 2008 revenue was 1.72 billion RMB ($252 million). That is up 24% over 2007, but at the low end of its previously announced 1.7 billion to 1.8 billion RMB estimated range. A...
- External links 2009-01-13
- Simcere Pharma Set to Produce Flu Drug in China
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) will seek approval from the SFDA to manufacture and sell products containing the flu drug zanamivir. Zanamivir was developed by GlaxoSmithKline (NYSE: GSK), which sells it under the brand name Relenza. Simcere has held a license to produce zanamivir since 2006,...
- External links 2009-05-06
- Simcere's Q1 Disappoints Investors
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) disappointed investors with its Q1 financial report. The company announced revenues of $64.8 million, a 12% increase from the year earlier, but $5 million less than the average analyst forecast. Net income was $7.1 million, a 57% decrease from 2008. At...
- External links 2009-05-20
- Simcere’s Q2 Fails Expectations
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR reported significantly improved Q2 financials Tuesday, but the results came in below analysts' estimates and the company reduced its guidance for full-year 2008. The disappointments caused a 4% selloff in the company’s stock price. Simcere makes branded generic pharmaceuticals for...
- External links 2008-08-06
- CHINA: LENOVO TEAMING UP WITH SIMCERE.
- According to fdi.gov.cn: Hong Yi Investment Management Company, the investment arm of Lenovo Holdings, recently celebrated its investment in the Nanjing-based pharmaceutical group Simcere. The project marks the first time that a ... According to fdi.gov.cn: Hong Yi Investment Management Company, the investment arm of...
- Research articles 2005-10-09
- Simcere Shows Positive Data from Cancer Drug Trial
- ChinaBio Today submits: Simcere Pharma SCR reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant...
- External links 2008-09-03
- Simcere's Q4: Revenues Up, Earnings Down
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR), which makes both branded generic pharmaceuticals and the anti-angiogenesis cancer drug Endu, reported Q4 revenues climbed 17% to 467 million RMB ($68.4 million), but net income fell 34% to 52 million RMB ($7.6 million). Simcere did not attribute the net income...
- External links 2009-03-13
- Simcere Pharma Follows Diversified Expansion Strategy
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) has entered an agreement to pay 195.5 million RMB ($28.8 million) for a 37.5% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd., a vaccine maker. Jiangsu Yanshen's major products include an influenza vaccine and a rabies vaccine vero cell for...
- External links 2009-05-27
- Simcere to Develop OSI Pharmaceutical Cancer Drug in China
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals, Inc. OSIP. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase...
- External links 2009-10-21
- Simcere Gains Majority Control of Vaccine Subsidiary
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR), a China company that makes branded generic and proprietary pharmaceuticals, now controls a majority 50.77% of its vaccine subsidiary, Jiangsu Yanshen Biological Technology Stock Co., Ltd. Simcere bought its original 37.5% stake in Jiangsu Yanshen in May 2009. Thursday, the company...
- External links 2009-10-30
- Simcere Pharmaceutical Group Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Shaojing Tong. Shaojing Tong - Bank of America-Merrill Lynch I just want to focus on this brand generic portfolio, whose sales fall substantially lower than the average normal level. You explained somewhat, but my focus was beyond...
- Earnings calls 2009-08-18
- Simcere Pharmaceutical Group Q2 2009 Earnings Call Transcript
- Simcere Pharmaceutical Group SCR Q2 2009 Earnings Call August 18, 2009 8:00 am ET
- External links 2009-08-18
- Simcere Teams Up with Cancer Center to Develop Drugs
- ChinaBio Today submits: Simcere Pharmaceutical Group (NYSE: SCR) and Sun Yat-Sen University Cancer Center of Guangzhou have established a strategic relationship to develop cancer drugs. In addition, the two companies will build a joint program to train personnel in advanced R&D. The company did not disclose any specifics about...
- External links 2009-08-24
- Zacks Releases Four Powerful "Buy" Stocks: PetMed Express, Sherwin-Williams, World Fuel Services and Simcere Pharmaceutical Group
- CHICAGO -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value....
- Research articles 2008-11-25
- CHINESE DRUG MAKER WENT PUBLIC IN NYSE
- AsiaInfo Services 04-24-2007 simcere+pharmaceutical+group[scr] Chinese Drug Maker Went Public in NYSE NANJING, Apr 24, 2007 SinoCast via COMTEX -- Simcere Pharmaceutical Group, a large medicine company in Nanjing, capital city of East C AsiaInfo Services ...
- Research articles 2007-04-24
- China Bio Week-in-Review: Trials and Deals
- ChinaBio Today submits: The news in China biotech last week revolved around two major topics: trial results/approvals and deals. On the test results front, Bridge Laboratories made a long-awaited announcement: the FDA accepted its China-developed data for review see story. Bridge submitted data from primate toxicology tests conducted in...
- External links 2008-09-07
- Six Key Chinese Healthcare ADRs
- Tom Malthus submits: As an additional follow-up to my ADR series see previous articles on energy sector ADRs and financial sector ADRS, I am going to take a look at the Chinese and Hong Kong healthcare sector. There are 6 key Chinese and Hong Kong ADRs within the GICS...
- External links 2008-08-08
- Webcast Alert: NYSE Euronext Virtual Investor Forum - Investing in Asia
- NEW YORK -- Simcere Pharmaceutical Group (NYSE: SCR) announces the following Webcast:
- Research articles 2007-10-08
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
